Tenon Medical Appoints Medical Device Veteran, Kevin Williamson, Chief Financial Officer Los Gatos, CA

Tenon Medical Appoints Medical Device Veteran,

Kevin Williamson, Chief Financial Officer

Los Gatos, CA - August 27, 2024 -

Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients

suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has appointed Kevin Williamson as Chief Financial Officer.

Mr. Williamson's appointment succeeds the previously disclosed retirement of Steve Van Dick from the role of Chief Financial Officer.

Mr. Williamson most recently served as the Chief

Financial Officer at Accelus Inc., a medical device company focused on expandable spinal implant technology. In this role, Mr. Williamson

was responsible for the finance organization, in addition to the investor relations and IT functions. From 2019 to 2020, Mr. Williamson

served in the Director of Finance position at Accelus Inc., where he was responsible for Financial Planning and Analysis. From 2015 to

2019, Mr. Williamson held various roles of increasing responsibility in the Corporate Finance department at NuVasive, Inc., a California-based

medical device company focused on minimally invasive spine surgery. Mr. Williamson holds a B.S. in Business Administration, Finance from

San Diego State University and an M.B.A. from the University of San Diego Knauss School of Business.

Steve Foster, Chief Executive Officer of Tenon,

commented, "With an extensive track record of financial leadership in the spinal related medical technology industry, we are thrilled

to welcome Kevin as Tenon's new Chief Financial Officer. As we near completion of upcoming catalysts, including full enrollment

of our post-market clinical trial for The Catamaran SI Joint Fusion System and the release of the study's interim analysis, Kevin's

vast experience as a CFO and finance professional will be instrumental to strategically advance Tenon into our next phase of growth."

Mr. Williamson said, "It is an honor to

join Tenon, and I would like to thank Steve and the Board for selecting me to fulfill this responsibility at this exciting

inflection point in the Company's growth trajectory. I look forward to leveraging my financial oversight experience of private and

public companies within the medical device industry by managing sustainable revenue while creating operating leverage, as Tenon penetrates

the SI market to achieve its objective of reducing chronic SI pain and driving long-term value."

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company

formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint

using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial

and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI joint along its longitudinal axis. The angle and trajectory

of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the

strongest cortical bone. Tenon is underway with a national launch of this system to address the greatly underserved market opportunity

that exists in this space. For more information, please visit www.tenonmed.com.

The Tenon Medical logo and Tenon Medical, are

registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.

Forward-Looking Statements

This press release contains "forward-looking

statements," which are statements related to events, results, activities or developments that Tenon Medical expects, believes or

anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates,"

"anticipates," "hopes," "projects," "plans," "expects," "seek,"

"believes," "see," "should," "will," "would," "target" and similar

expressions and the negative versions thereof. Such statements are based on Tenon Medical's experience and perception of current

conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only

as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates

or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties

that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our

Annual Report on Form 10-K on file with the Securities and Exchange Commission ("SEC") at www.sec.gov, particularly the information

contained in the section entitled "Risk Factors," and other SEC filings. We undertake no obligation to publicly update or

revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.